Ticker: $ANGO 🚀💉
Price: $11.17 (+4.00%) as of Sep 30, 2025, 4:00 PM ET

Trigger 1: Insider Buys That Aged Like Fine Wine 🍷

Let’s rewind. Back in October 2024, AngioDynamics’ CEO James Clemmer, CFO Stephen Trowbridge, and SVP Warren Nighan all loaded up on company stock around $6 per share.

• Clemmer: +20,000 shares at $6.03.

• Trowbridge: +1,700 shares at $5.86.

• Nighan: +868 shares at $6.09.

Fast-forward one year: $ANGO is now ~$11. Translation: they basically doubled their money. 🎯

That’s not just foresight, that’s insider swagger.

Trigger 2: Institutions Are All-In 📊🐋

Insiders hold about 6% of shares, but the real story? Institutions own nearly all of it:

• 92.82% of shares are institution-owned.

• 99.17% of float is locked up in funds.

• 188 institutional holders total.

The list includes the usual suspects:

• BlackRock 🏢 (3.5M shares)

• Vanguard 📈 (2.5M)

• Point72 🐯 (nearly doubled their stake)

• Divisadero Street Capital (+253% growth in shares!)

This isn’t a meme stock run by Redditors in pajamas (at least not yet :)). Institutions basically own the company’s wardrobe.

For AngioDynamics (ANGO)'s Institutional Ownership breakdown, 🔍 see here.

Trigger 3: Earnings Incoming (Oct 2) 🎤💥

Earnings are days away. That means one thing: short-term volatility. Buckle up, because medical tech small caps like ANGO tend to move like caffeinated squirrels around earnings time. 🐿️⚡

What Does AngioDynamics Even Do? 🩺🔬

Based in Latham, NY, AngioDynamics makes medical devices for vascular disease, oncology, and surgical settings. Their product menu sounds like it belongs in a superhero arsenal:

• Auryon Atherectomy: Laser device that removes blockages without damaging vessel walls.

• AlphaVac Thrombectomy: Clears clots like a plumbing snake for your veins. 🚰

• NanoKnife: Soft-tissue ablation with electricity instead of heat. FDA-approved for prostate cancer, expanding into pancreas in 2027.

• AngioVac Cannula: Supports extracorporeal circulation (think mini heart-lung machine).

• Solero Microwave Ablation: Microwave tech for tissue ablation.

They’ve been around since 1988 and have reinvented themselves into a leaner, more focused MedTech growth company (after completing the sale of their PICC and Midline product portfolios and discontinuing their Uniblate and Starburst Radio Frequency products, as well as other offerings). Portfolio optimization enhances strategic focus.

Financial Pulse Check 💰🫀

Q4 2025 Highlights (ended May 31, 2025):

• Net Sales: $80.2M (+12.7% YoY).

• MedTech Sales: $35.8M (+22%).

• Adjusted EBITDA: +$3.4M (positive momentum).

• Free Cash Flow: +$16.2M.

• Cash on Hand: $55.9M.

Full-Year 2025 Highlights:

• Net Sales: $292.7M (+8.1%).

• MedTech Sales: $126.7M (+19.5%).

• Adjusted EBITDA: $7.6M (positive).

• Cash & Equivalents: $55.9M.

Notably: they’ve shrunk their losses and are building a consistent record of positive adjusted EBITDA and free cash flow generation.

👉 Want the full picture? Dive into AngioDynamics (ANGO)'s financials here.

Why It Matters 🧭

1. Growth Engines: MedTech sales growing >20%, powered by NanoKnife, AlphaVac, and Auryon.

2. Market Tailwinds: Aging population, chronic disease rise, demand for minimally invasive procedures.

3. Strategic Wins: FDA approvals, reimbursement codes (CPT Category I for NanoKnife), and expanding global footprint.

4. Valuation: On classic metrics (Price/Sales, Price/Book), ANGO looks cheap compared to growth potential.

5. Institutional Confidence: Nearly 100% float owned by funds. That’s rare and bullish.

Valuation Snapshot 📊💡

• Market Cap: $438.7M

• Price/Sales: 1.49 (cheap vs medtech peers).

• Price/Book: 2.40 (reasonable).

• Forward P/E: ~96 [high, but distorted by low (just rerating) current earnings)].

• EV/Revenue: 1.36 (cheap).

So, if you just look at P/E, you’ll faint. But if you look at growth + revenue multiples, it’s not crazy.

The Bull Case 🐂

• Insider buys aged perfectly, showing confidence.

• Institutions practically own the float.

• Strong MedTech growth (+20%+).

• Positive adjusted EBITDA + free cash flow.

• Trades 2/3 below 2021 highs ($32).

The Bear Case 🐻

• Tariffs still pressure margins.

• Supply chain + labor efficiency hurdles.

• Still not consistently GAAP profitable.

• Small-cap risk: volatile, sometimes overlooked.

• Forward P/E looks scary at a glance.

💡💡💡 Curious about another deep oil exploration play?
👉 Check our take on UnitedHealth Group.

FAQ ❓💬

Q: Didn’t insiders already cash in?
A: Nope — they’re still holding. That’s conviction.

Q: Who owns this thing?
A: Institutions. Nearly 100% float. It’s basically Wall Street’s pet medtech.

Q: Why earnings Oct 2 matter?
A: Small caps swing wildly on earnings beats/misses. Expect fireworks. 🎆

Q: Is it cheap?
A: By Price/Sales & Price/Book, yes. By P/E, no (but fails to account for future growth runway). Depends on which lens you wear.

Quick Take / TL;DR ⚡📌

• Insider buys in 2024 doubled in value.

• Institutions own almost the entire float.

• Earnings Oct 2 = short-term volatility.

• MedTech growth engines firing (+20% sales).

• Valuation: cheap on sales/book, scary on P/E.

• Upside: stock still 2/3 below 2021 ATH.

👉 Translation: ANGO is a small-cap medtech stock with insider conviction, institutional backing, and strong growth — but it comes with tariffs, supply chain headaches, and small-cap volatility. 🎢